Want to join the conversation?
$IDRA expects initiating a Phase 2 clinical trial of IMO-8400 in dermatomyositis in 4Q15. The company may enroll approx. 48 patients in the trial which it expects to conduct at approx. 20 clinical sites. As of Sept. 30, 2015, $IDRA had an accumulated deficit of $488MM and anticipates incurring substantial operating losses in future periods.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.